Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture
April 3, 2024
Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.
EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.
Contributors: Dr. Adrian Lau, Dr. Heather McDonald-Blumer, Dr. Sandra Kim, Dr. Natasha Gakhal, Dr. Lianne Tile, Dr. Angela Cheung, Dr. Julie Gilmour, Dr. Laëtitia Michou, Dr. Claudia Gagnon, Dr. Zahra […]
FDA Qualifies First Surrogate Endpoint For Use In Osteoporosis Clinical Trials
December 22, 2025
Update On Clinical Trials FDA Qualifies First Surrogate Endpoint For Use In Osteoporosis Clinical Trials December 22, 2025 Osteoporosis Canada is excited to share the US Food and Drug Administration […]
World Health Organization (WHO) publishes article on benchmarks for equitable hip-fracture care and osteoporosis treatment in older people
December 9, 2025
Latest News World Health Organization (WHO) publishes article on benchmarks for equitable hip-fracture care and osteoporosis treatment in older people December 9, 2025 In Canada, one in three hip fracture […]
